13 May Product Development Market Update:"Portfolio Update SUDA...

13 May Product Development Market Update:

"Portfolio Update SUDA has a broad portfolio of projects at various stages of development. 14 projects are classified as Investigational New Drug Status (IND) and 11 projects with clinical proof of concept or extensive clinical data. SUDA’s board and management acknowledge that the Company needs to focus on delivering a select number of key projects and to deliver shareholder return.

As a result, SUDA is actively developing Anagrelide and Midazolam oral sprays for the market. The board believes these drugs, due to their market size and unique attributes which make them ideal candidates for reformulation, can deliver substantial long term returns to shareholders.

Outside these two priority drugs, we are actively carrying out work on fully funded co-development projects for partners on Sumatriptan and Cannabinoids, and we are carrying out funded contract work on existing contracts around the ZolpiMist project. All other projects are on hold and will only be continued with third party funding through partnerships (co-development or feasibility studies).

The board believes that this will provide the best return for our shareholders. "

So SUD stated here there has been an emphasis on slowing the cash burn, focussing on products they can monetise best and fully funded co development deals.

Then Hopper sends Carter on an around the world SUD marking trip - don't think he's travelling economy or staying in a formula 1 motor inn do you?...after all, he luffed us all into handing over more cash recently so better put it to good use right???